T. Ganz, Systemic Iron Homeostasis, Physiological Reviews, vol.93, issue.4, pp.1721-1762, 2013.
DOI : 10.1152/physrev.00008.2013

URL : http://physrev.physiology.org/content/physrev/93/4/1721.full.pdf

G. Papanikolaou and K. Pantopoulos, Systemic iron homeostasis and erythropoiesis, IUBMB Life, vol.38, issue.120, pp.399-413, 2017.
DOI : 10.1111/ijlh.12505

S. Recalcati, E. Gammella, P. Buratti, and G. Cairo, Molecular regulation of cellular iron balance, IUBMB Life, vol.7, issue.6, pp.389-98, 2017.
DOI : 10.3389/fphar.2016.00160

T. Ganz and E. Nemeth, Hepcidin and iron homeostasis, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1823, issue.9, pp.1434-1477, 2012.
DOI : 10.1016/j.bbamcr.2012.01.014

URL : https://doi.org/10.1016/j.bbamcr.2012.01.014

T. Ganz, Hepcidin???a regulator of intestinal iron absorption and iron recycling by macrophages, Best Practice & Research Clinical Haematology, vol.18, issue.2, pp.171-82, 2005.
DOI : 10.1016/j.beha.2004.08.020

G. Papanikolaou, M. Tzilianos, J. Christakis, D. Bogdanos, K. Tsimirika et al., Hepcidin in iron overload disorders, Blood, vol.105, issue.10, pp.4103-4108, 2005.
DOI : 10.1182/blood-2004-12-4844

URL : http://www.bloodjournal.org/content/bloodjournal/105/10/4103.full.pdf

A. Kattamis, I. Papassotiriou, D. Palaiologou, F. Apostolakou, A. Galani et al., The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major, Haematologica. juin, vol.91, issue.6, pp.809-821, 2006.

T. Tanno, N. Bhanu, P. Oneal, S. Goh, P. Staker et al., High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, Nature Medicine, vol.33, issue.9, pp.1096-101, 2007.
DOI : 10.1016/S0167-4781(97)00122-X

G. Casanovas, D. Swinkels, S. Altamura, K. Schwarz, C. Laarakkers et al., Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II, Journal of Molecular Medicine, vol.115, issue.8, pp.811-817, 2011.
DOI : 10.1182/blood-2009-09-238105

H. Tamary, H. Shalev, G. Perez-avraham, M. Zoldan, I. Levi et al., Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I, Blood, vol.112, issue.13, pp.5241-5245, 2008.
DOI : 10.1182/blood-2008-06-165738

URL : http://www.bloodjournal.org/content/bloodjournal/112/13/5241.full.pdf

T. Tanno, P. Porayette, O. Sripichai, S. Noh, C. Byrnes et al., Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, vol.114, issue.1, pp.181-187, 2009.
DOI : 10.1182/blood-2008-12-195503

. Hémochromatose and ]. Internet, Disponible sur: https://www.inserm.fr/thematiques/physiopathologie-metabolisme-nutrition/dossiers-d- information/hemochromatose-genetique, 2017.

. Betathalassemie-frfrpub51, pdf [Internet]. [cité 14 juill 2017] Disponible sur: https://www.orpha.net/data

I. Thuret, C. Pondarré, A. Loundou, D. Steschenko, R. Girot et al., Complications and treatment of patients with ??-thalassemia in France: results of the National Registry, Haematologica, vol.95, issue.5, pp.724-733, 2010.
DOI : 10.3324/haematol.2009.018051

S. Allali, M. De-montalembert, V. Brousse, M. Chalumeau, and Z. Karim, Management of iron overload in hemoglobinopathies, Transfusion Clinique et Biologique, vol.24, issue.3, 2017.
DOI : 10.1016/j.tracli.2017.06.008

R. Ware, M. De-montalembert, L. Tshilolo, and M. Abboud, Sickle cell disease. The Lancet
URL : https://hal.archives-ouvertes.fr/inserm-00696264

B. Yawn, G. Buchanan, A. Afenyi-annan, S. Ballas, K. Hassell et al., Management of Sickle Cell Disease, JAMA, vol.312, issue.10, pp.1033-1081, 2014.
DOI : 10.1001/jama.2014.10517

R. Adams and D. Brambilla, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease, N Engl J Med. 29 déc, vol.353, issue.26, pp.2769-78, 2005.
DOI : 10.1016/s0197-2456(97)00099-8

R. Grace, A. Zanella, E. Neufeld, D. Morton, S. Eber et al., Erythrocyte pyruvate kinase deficiency: 2015 status report, American Journal of Hematology, vol.124, issue.9, pp.825-855, 2015.
DOI : 10.1016/0009-8981(75)90074-1

URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.24088/pdf

A. Vlachos, S. Ball, N. Dahl, B. Alter, S. Sheth et al., Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference, British Journal of Haematology, vol.101, issue.Suppl 3, pp.859-76, 2008.
DOI : 10.1111/j.1442-200X.1992.tb00947.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07269.x/pdf

P. Halonen, J. Mattila, P. Suominen, T. Ruuska, M. Salo et al., Iron Overload in Children Who Are Treated for Acute Lymphoblastic Leukemia Estimated by Liver Siderosis and Serum Iron Parameters, PEDIATRICS, vol.111, issue.1, pp.91-97, 2003.
DOI : 10.1542/peds.111.1.91

G. Anderson, Mechanisms of iron loading and toxicity, American Journal of Hematology, vol.25, issue.S12, pp.1128-1159, 2007.
DOI : 10.1152/ajpgi.00220.2005

URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.21075/pdf

D. Sanctis, V. Soliman, A. Elsedfy, H. Skordis, N. Kattamis et al., Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines, Indian Journal of Endocrinology and Metabolism, vol.17, issue.1, pp.8-18, 2013.
DOI : 10.4103/2230-8210.107808

V. Berdoukas, A. Nord, S. Carson, M. Puliyel, T. Hofstra et al., Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age, American Journal of Hematology, vol.87, issue.11, pp.283-285, 2013.
DOI : 10.1002/ajh.22247

D. Sanctis, V. Soliman, A. Elsedfy, H. Pepe, A. Kattamis et al., Diabetes and Glucose Metabolism in Thalassemia Major: An Update, Expert Review of Hematology, vol.88, issue.2, pp.401-409, 2016.
DOI : 10.4081/thal.2013.s1.e18

K. Huang, S. Mittelman, T. Coates, M. Geffner, and J. Wood, A Significant Proportion of Thalassemia Major Patients Have Adrenal Insufficiency Detectable on Provocative Testing, Journal of Pediatric Hematology/Oncology, vol.37, issue.1, pp.54-63, 2015.
DOI : 10.1097/MPH.0000000000000199

M. De-montalembert, J. Ribeil, V. Brousse, A. Guerci-bresler, A. Stamatoullas et al., Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome, PLOS ONE, vol.6, issue.8, p.172147, 2017.
DOI : 10.1371/journal.pone.0172147.t004

E. Angelucci, G. Brittenham, C. Mclaren, M. Ripalti, D. Baronciani et al., Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major, New England Journal of Medicine, vol.343, issue.5, pp.327-358, 2000.
DOI : 10.1056/NEJM200008033430503

P. Jensen, F. Jensen, T. Christensen, H. Eiskjaer, U. Baandrup et al., Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool, Blood, vol.101, issue.11, pp.4632-4641, 2003.
DOI : 10.1182/blood-2002-09-2754

J. Wood, B. Kang, A. Thompson, P. Giardina, P. Harmatz et al., The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores, Blood, vol.116, issue.4, pp.537-580, 2010.
DOI : 10.1182/blood-2009-11-250308

G. Brittenham, P. Griffith, A. Nienhuis, C. Mclaren, N. Young et al., Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major, New England Journal of Medicine, vol.331, issue.9, pp.567-73, 1994.
DOI : 10.1056/NEJM199409013310902

G. Brittenham, D. Farrell, J. Harris, E. Feldman, E. Danish et al., Magnetic-Susceptibility Measurement of Human Iron Stores, New England Journal of Medicine, vol.307, issue.27, pp.1671-1676, 1982.
DOI : 10.1056/NEJM198212303072703

D. Brown, R. Henkelman, P. Poon, and M. Fisher, Nuclear magnetic resonance study of iron overload in liver tissue, Magnetic Resonance Imaging, vol.3, issue.3, pp.275-82, 1985.
DOI : 10.1016/0730-725X(85)90357-1

T. Coates and J. Wood, How we manage iron overload in sickle cell patients, British Journal of Haematology, vol.312, issue.5, pp.703-719, 2017.
DOI : 10.1001/jama.2014.10517

R. Osborne, D. Abreu-lourenço, R. Dalton, A. Houltram, J. Dowton et al., Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study, Value in Health, vol.10, issue.6, pp.451-457, 2007.
DOI : 10.1111/j.1524-4733.2007.00200.x

M. Al-kloub, T. Salameh, and E. Froelicher, Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents, International Journal of Nursing Practice, vol.40, issue.3, pp.265-74, 2014.
DOI : 10.1080/02739615.2011.537934

A. Taher, A. El-beshlawy, M. Elalfy, A. Zir, K. Daar et al., Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with ??-thalassaemia: the ESCALATOR study, European Journal of Haematology, vol.91, issue.6, pp.458-65, 2009.
DOI : 10.1111/j.1600-0609.2009.01228.x

Y. Aydinok, S. Unal, Y. Oymak, C. Vergin, Z. Türker et al., Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-na??ve children with transfusional iron overload, European Journal of Haematology, vol.87, issue.5, pp.431-439, 2012.
DOI : 10.1111/j.1600-0609.2011.01662.x

J. Kwiatkowski, Current recommendations for chelation for transfusion-dependent thalassemia, Annals of the New York Academy of Sciences, vol.95, issue.1, pp.107-121, 2016.
DOI : 10.1111/ejh.12507

E. Vichinsky, Clinical application of deferasirox: Practical patient management, American Journal of Hematology, vol.91, issue.5, pp.398-402, 2008.
DOI : 10.1002/ajh.21119

URL : http://onlinelibrary.wiley.com/doi/10.1002/ajh.21119/pdf

R. Galanello, A. Piga, M. Cappellini, G. Forni, A. Zappu et al., Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen, The Journal of Clinical Pharmacology, vol.509, issue.4, pp.428-463, 2008.
DOI : 10.1007/978-1-4615-0593-8_10

F. Mattioli, M. Puntoni, V. Marini, C. Fucile, G. Milano et al., Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?, European Journal of Haematology, vol.24, issue.894, pp.310-317, 2015.
DOI : 10.1097/00007691-200202000-00018

R. Galanello, A. Piga, G. Forni, Y. Bertrand, M. Foschini et al., Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with betathalassemia major, Haematologica. oct, vol.91, issue.10, pp.1343-51, 2006.

E. Chauzit, S. Bouchet, M. Micheau, F. Mahon, N. Moore et al., A Method to Measure Deferasirox in Plasma Using HPLC Coupled With MS/MS Detection and its Potential Application, Therapeutic Drug Monitoring, vol.32, issue.4, pp.476-81, 2010.
DOI : 10.1097/FTD.0b013e3181d8b37f

R. Fischer and P. Harmatz, Non-invasive assessment of tissue iron overload, Hematology, vol.2009, issue.1, 2009.
DOI : 10.1182/asheducation-2009.1.215

Y. Lai, R. Liu, C. Li, S. Huang, Q. Li et al., Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial, Transfusion Medicine, vol.15, issue.6, pp.389-96, 2013.
DOI : 10.1080/03670244.1984.9990804

E. Vichinsky, F. Bernaudin, G. Forni, R. Gardner, K. Hassell et al., Long-term safety and efficacy of deferasirox (Exjade??) for up to 5???years in transfusional iron-overloaded patients with sickle cell disease, British Journal of Haematology, vol.1, issue.Suppl. 1, pp.387-97, 2011.
DOI : 10.1016/j.jpeds.2005.02.030

E. Vichinsky, A. El-beshlawy, A. Zoebie, A. Kamdem, A. Koussa et al., Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST) Pediatr Blood Cancer, 2017.

N. Costedoat-chalumeau, F. Houssiau, P. Izmirly, L. Guern, V. Navarra et al., A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires, Clinical Pharmacology & Therapeutics, vol.1, 2017.
DOI : 10.1186/1477-7525-1-29

N. Vande-casteele, H. Herfarth, J. Katz, Y. Falck-ytter, and S. Singh, American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases, Gastroenterology, vol.153, issue.3, pp.835-857, 2017.
DOI : 10.1053/j.gastro.2017.07.031

R. Galanello, A. Piga, D. Alberti, M. Rouan, H. Bigler et al., Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to ??-Thalassemia, The Journal of Clinical Pharmacology, vol.755, issue.6, pp.565-72, 2003.
DOI : 10.1016/S0378-4347(01)00079-2

C. Tanaka, Clinical Pharmacology of Deferasirox, Clinical Pharmacokinetics, vol.120, issue.21, pp.679-94, 2014.
DOI : 10.1182/blood-2009-04-217455

S. Allegra, D. Francia, S. Cusato, J. Arduino, A. Massano et al., Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients, Pharmacogenomics, vol.20, issue.8, pp.539-54, 2017.
DOI : 10.18632/oncotarget.1050

A. Taher, M. Elalfy, A. Zir, K. Daar, S. et al., Importance of optimal dosing ???30???mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with ??-thalassaemia, European Journal of Haematology, vol.147, issue.Suppl 2, pp.355-65, 2011.
DOI : 10.1111/j.1365-2141.2009.07908.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2011.01662.x/pdf

P. Ho, L. Tay, J. Teo, P. Marlton, A. Grigg et al., Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study), European Journal of Haematology, vol.147, issue.11, pp.97-105, 2017.
DOI : 10.1111/j.1365-2141.2009.07908.x

L. Dubourg, C. Laurain, B. Ranchin, C. Pondarré, A. Hadj-aïssa et al., Deferasirox-induced renal impairment in children: an increasing concern for pediatricians, Pediatric Nephrology, vol.32, issue.Suppl 2, pp.2115-2137, 2012.
DOI : 10.1097/MPH.0b013e3181ec0c4d

V. Dell-'orto, M. Bianchetti, and P. Brazzola, Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature, Journal of Clinical Pharmacy and Therapeutics, vol.32, issue.6, pp.526-533, 2013.
DOI : 10.1097/MPH.0b013e3181ec0c4d

M. Rheault, H. Bechtel, J. Neglia, and C. Kashtan, Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer, avr, vol.56, issue.4, pp.674-680, 2011.

M. Marano, G. Bottaro, B. Goffredo, F. Stoppa, M. Pisani et al., Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis, European Journal of Clinical Pharmacology, vol.30, issue.2
DOI : 10.1038/clpt.1981.154

C. Delaby and C. Beaumont, Serum hepcidin assay in 2011: where do we stand?], Ann Biol Clin août, vol.70, issue.4, pp.377-86, 2012.